Login to Your Account

Pharma: Other News To Note

Monday, August 6, 2012
• GlaxoSmithKline plc (GSK), of London, said it submitted applications in the European Union and the U.S. for use of its BRAF inhibitor dabrafenib as a treatment for adults with unresectable or metastatic melanoma with a BRAF V600 mutation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription